Cancer Cell-targeting Carrier: NanoDex-001 (ND1) for Cancer Therapy and Imaging Diagnosis
Comprehensive contract covering 1) through 3) below would be appreciated, since NanoDex Inc. offers a bulk supply of following products:
1) Approval of patent license
2) Consigned research on patents
3) Provision of samples relating to ND1 and its derivatives
As shown above, since folate cluster-type cyclodextrin ND1 specifically accumulates in epithelial cancers, especially in digestive system cancer, epithelial lung cancer and ovarian cancer that overexpress folate receptors, it can be effectively applied to 1) diagnoses of these cancers, 2) a tumor marker and 3) cancer treatment.
The patent possessed by NanoDex:
1） WO 2009/041666; The materials, production and cancer-targeting ability of ND1
2） Japanese Published Unexamined Patent Application No. 2008-28567;
The materials, production and organ (lever, macrophage, colon) targeting ability of glycosylated cyclodextrin
3) Japanese Patent Application No. 2010-057243; The materials and production of ND1 derivatives.
NanoDex Inc.: email@example.com http://www.nanodex.jp TEL & FAX +81-46-244-0595
President: Dr. Kenjiro Hattori, firstname.lastname@example.org
Address of R&D laboratory: Kanagawa Industrial Technical Center 1F 1-2,
705-1 Imaizumi, Ebina, Kanagawa, Japan 243-0435